Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: A decision analysis model  by Huber, Thomas S. et al.
Intraoperative autologous transfusion 
during elective infrarenal aortic 
reconstruction: A decision analysis model 
Thomas  S. Huber ,  MD,  PhD,  Susan P. McGorray ,  PhD,  Lor i  C. Car l ton ,  RN,  
Ph i l ip  B. I rw in ,  PA,  R ichard  R. F lug ,  MA,  RN,  T imothy  C. F lynn ,  MD,  and 
James M.  Seeger,  MD,  Gainesville, Fla. 
Purpose: The use of  intraoperative autologous transfusion devices expanded uring the 
last decade as a result o f  the increased awareness of  transfusion-associated complications. 
This study was designed to determine whether routine use of  an intraoperative autolo- 
gnus transfusion device (Haemonetics Cell Saver [CS]) during elective infrarenal aortic 
reconstructions is cost-effective ($50,000/QALYs threshold). 
Methods: A decision analysis tree was constructed to model all of  the complications that 
are associated with red blood cell replacement during aortic reconstructions for both 
abdominal aortic aneurysm (AAA) and aortoil iac occlusive disease (AIOD). I t  was 
assumed that a unit o f  CS return (CSR; 250 ml /un i t )  equaled a unit of  packed red blood 
cells (PRBCs) and that all CS transfusions were necessary. Transfusion requirements 
(AAA: PRBC = 2.8 _ 3.2 units, CSR = 3.7 - 3.2 units; A IOD:  PRBC = 3.1 -+ 3.0 units, 
CSR = 2.1 + 1.7 units) were determined from retrospective r view of  all elective aortic 
reconstructions (AAA, N = 63; A IOD,  N=75)  from Jan. 1991 to June 1995 in which the 
CS was used (82.1% of  all reconstructions). Risk of  allogenic transfusion-related compli- 
cations (transfusion reaction, hepatitis B, hepatitis C, human immunodeficiency virus, 
human T-cell lymphotropic virus types I and I I)  and their associated treatment costs 
(expressed in dollars and quality-adjusted life years (QALYs) were obtained from the 
medical l iterature, institutional audit, and a consensus of  physicians. 
Results: Routine use of  the CS during elective infrarenal aortic reconstructions was not 
cost-effective in our practice. Use during reconstructions for AAA repairs cost $263.75 
but  added only 0.00218 QALYs, for a rate of  $120,794/QALY.  Use during reconstruc- 
tions for A IOD was even more cosily at $356.68 and provided even less benefit at 
0.00062 QALYs, for a rate of  $ 578,275/QALY.  The sensitivity analyses determined that 
the routine use of  the CS would be cost-effective in our practice only for AAA repairs i f  
the incidence of  hepatitis C were tenfold greater than the baseline assumption. The model 
determined that CS was cost-effective if the CSR exceed 5 units during reconstructions 
for AAA and 6 units during reconstructions for A IOD.  
Conclusions: The routine use of  the CS during elective infrarenal aortic reconstructions is 
not cost-effective. The use of  the device should be reserved for a select group of  aortic 
reconstructions, including those in which cost-effective salvage volumes are anticipated. 
Alternatively, the CS should be used as a reservoir and activated as a salvage device if 
significant bleeding is encountered. (] Vasc Surg 1997;25:984-94.) 
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Fig. 1. Decision analysis model incorporates allpossible outcomes associated with red blood 
cell salvage and transfusion during aortic reconstruction. The root node ([2) represents he 
decision to use the IOAT device. © nodes reflect events that occur by chance. ~ nodes 
represent outcomes independent of the aortic reconstruction a d transfusion complications 
modeled in the analysis. • nodes represent deaths that result from the operative procedure or 
the transfusion-related complications modeled. • nodes represent processes modeled by 
Markov analyses. 
ing aortic reconstructions is not well defined. Ouriel 
et al. 1 and Cutler 2 reported that IOAT during aortic 
procedures resulted in significant blood product sav- 
ings, although the costs of the devices were not 
factored into either analysis and hospital charge 
rather than cost data were used in the latter. Like- 
wise, Reddy et al. 3 and Tawes et al. 4 reported that 
IOAT was cost-effective if the blood salvage volume 
was greater than 2 units, but the details of the cost- 
effectiveness analyses were not reported in either 
study. In contrast, Kelley-Patteson et al.s reported 
that IOAT was not cost-effective during aortic recon- 
structions for occlusive disease in a prospective, ran- 
domized study. Similarly, Goodnough et al. 6 re- 
ported that the cost of the blood products alvaged 
during elective aortic reconstructions for aneurysms 
accounted for only 79% of the cost of the IOAT 
device, and they concluded that the use of the device 
was not beneficial if the anticipated blood loss was 
less than 1000 ml. The conclusions from all of these 
studies, however, were limited by the means of as- 
sessing the cost-effectiveness. 
Appropriate cost-effectiveness assessments of 
IOAT and other medical practices are contingent on 
the ratio of the costs (dollars) to the benefits pro- 
vided. The latter is commonly expressed in quality- 
adjusted life years (QALYs) to allow comparison 
between disparate practices. Appraisal of the cost- 
effectiveness of IOAT must incorporate the cost of 
the device and the savings realized from avoiding 
allogenic blood transfusions. These include the cost 
of the blood products themselves and all of the costs 
and the QALYs lost as a result of the immediate-term 
and long-term transfusion-associated complications. 
Interestingly, Birkmeyer et al. 7 and Etchason et at.8 
recently reported that preoperative autologous dona- 
tions were not cost-effective even when all of the 
associated costs and benefits were modeled. This 
study was designed to determine whether outine use 
of an IOAT device (Haemonetics Cell Saver [CS], 
Braintree, Mass.) during elective infrarenal aortic re- 
construction is cost-effective using a decision analysis 
model. 
PATIENTS AND METHODS 
Experimental design 
A decision analysis tree was constructed (Deci- 
sion Analysis, Tree Age; Boston, Mass.) to model all 
of the possible outcomes associated with red blood 
cell replacement during elective infrarenal aortic re- 
construction. 7,8 A schematic of the decision tree is 
shown in Fig. l ,  and the values used for the variables 
are summarized in Table I. The payoff of each possi- 
ble outcome was expressed in terms of dollars and 
QALYs. Cost-effectiveness of the CS was determined 
by the equation (COSTcs -  COSTNocs)/(QALYcs 
- QALY>aoCS) , where the COST and QALY variables 
reflect he aggregate values associated with the deci- 
sion to use or not use the CS. The threshold for 
cost-effectiveness was defined at $50,000/QALY. 9,1° 
The decision tree was constructed on the basis of the 
assumptions that a unit of blood salvaged by the CS 
was comparable with a unit of  allogenic packed red 
blood cells (PRBCs) and that it was necessary to 
transfuse all of  the blood salvaged by the CS. Thus it 
was assumed that a unit of blood salvaged by the CS 
represented a unit of allogenic PRBCs that would 
have been transfused had the device not been used. 
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Tab le  I. Values assigned to decision analysis variables 
Variable Value Sensitivity range 
Operative death 
AAA reconstruction 12,13 
AIOD reconstruction 12,13 
Transfusion reaction (per unit pRBC) 
Fatal 7
Nonfatal 7 
Transfusion i fections (per unit PRBC) 
Hepatitis C7,8 
Hepatitis B7,8 
HIVT,S,3S 
HTLV I/ I I  7'8 
Transfusion i fection outcome 
Fulminant hepatitis 7,8 
Hospitalization acute hepatitis 7,8 
Symptoms acute hepatitis 7,8 
Hepatitis C resolve 7,8 
Symptomatic chronic hepatitis C7'8 
Hepatitis B resolve 7,s 
Symptomatic chronic Hepatitis B7,8 
CAH B or C 7,s 
Interferon for CAH B or C 7,s 
Liver biopsy if interferon (CAH B or C) 7,s 
HTLV I/ I I  myelopathy 7,s
Quality of life adjustments 
Symptoms acute hepatitis (yr) 7,8 
Hospitalization acute hepatitis (yr) 7,s 
Liver biopsy (yr) 7,s 
Interferon therapy (yr) 7,s 
Symptomatic chronic Hepatitis B or C (per yr) 7,s 
Asymptomatic chronic Hepatitis B or C (per yr) 7,s 
HIV infection (pre-AIDS, per yr) 7,8 
AIDS (per yr) 7,8 
HTLV I/ I I  myelopathy (per yr) 7,s 
Costs (dollars) 
First unit allogenic PRBC 
Each additional unit allogenic PRBC 
CS 
Nonfatal transfusion reaction 
Evaluation for acute symptomatic hepatitis 
Hospitalization acute hepatitis 
Liver biopsy 
Interferon therapy 7 
Follow-up for chronic hepatitis (per yr) 
HTLV myelopathy (per yr) 7 
HIV/AIDS (per yr) 
Life expectancy 
AAA reconstruction (yr) 14q6 
Excess mortality for AAA ~7,1s 
AIOD reconstruction (yr) 14-16 
Excess mortality for AIOD (pr yr) x9 
HIV/AIDS (yrs) s
Excess mortality for chronic hepatitis (per yr) 7 
0.063 0.01-0.1 
0.057 0.01-0.1 
0.0001 0.00001-0.001 
0.000002 0.0000002-0.00002 
0.0003 0.00003-0.003 
0.000005 0.0000005-0.00005 
0.0000022 0.00000022-0.000022 
0.000017 0.00000017-0.00017 
0.005 0.0005-0.05 
0.025 0.01-0.05 
0.25 0.15-0.40 
0.5 0.25-0.75 
0.075 0.05-0.10 
0.9 0.8-0.95 
0.015 0.01-0.02 
0.4 0.3-0.6 
0.5 0-1.0 
1.0 
0.01 0.001-0.1 
0.0385 0.0192-0.0769 
0.0192 0.0096-0.0385 
0.0055 0.0027-0.0192 
0.0385 0.0192-0.0769 
0.90 0.75-0.95 
0.99 0.95-1 
0.5 0.3-0.8 
0.25 0-0.5 
0.9 0.75-0.95 
86.99 
55.83 
477.74 
1800 1,200-2,400 
3000 2,000-4,000 
33,000 20,000-50,000 
400 300-2000 
4300 3,500-6,000 
3,000 2,000-4,000 
12,000 5,000-50,000 
10,000 5,000-50,000 
12.3 
none 
17.63 
0.059 
9 
0.0035 
CA/-/, Chronic active hepatitis. 
Furthermore, it was assumed that there were no 
complications associated with the use of  salvaged 
blood. Separate decision analyses were performed for 
patients who underwent  aortic reconstruction for 
abdominal aortic aneurysm (AAA) and aortoiliac oc- 
clusive disease (AIOD) because of the decreased age- 
adjusted life expectancy, smaller transfusion volumes, 
and the smaller percentage of the estimated blood 
loss salvaged in the latter group. Sensitivity analyses 
were used to examine the stability of the conclusions 
based on the assumptions incorporated in the model 
for the outcome probabilities, costs, and QALYs. 
Additional analyses were performed to potentially 
identify subsets of  patients in whom use of the CS 
would be cost-effective. The impact of life expect- 
ancy, volume of blood salvaged by the CS, the CS 
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cost, and the cost of a unit ofallogenic PRBCs on the 
overall cost-effectiveness were examined. 
Decision analysis data 
Patient care and transfusion requirements. 
The hospital records of all patients who underwent 
elective infrarenal aortic reconstruction using the CS 
from January 1991 through June 1995 were retro- 
spectively reviewed. The CS was used in 138 of the 
168 reconstructions (82.1%) during the time period. 
It was routinely used during all elective aortic recon- 
structions during this period but was unavailable or 
was not requested uring 30 cases. Patient demo- 
graphics, medical history, details of  the operative 
procedure, and the perioperative transfusion require- 
ments were all determined. 11The perioperative pe- 
riod was defined from the start of the operation to 24 
hours after surgery and was chosen to most accu- 
rately account for the resuscitation from the intraop- 
erative bleeding. The transfusion requirements for all 
patients who underwent aortic reconstructions for 
either indication along with the subsets analyzed are 
shown in Table II. As noted above, it was assumed 
that the blood salvaged by the CS represented allo- 
genie PRBCs that would have been transfused had 
the device not been used. Specifically, amean of 6.5 
and 5.2 units of allogenic PRBCs would have been 
transfused for reconstructions performed for AAA 
and AIOD, respectively, without the CS. 
Outcome probabilities. The operative mortal- 
ity rates (6.3% for AAA, 5.7% for AIOD) were de- 
fmed by a previous retrospective r view of all 722 
elective infrarenal aortic reconstructions performed 
at our institution over a 12-year period inclusive of 
those procedures performed concomitant with either 
lower extremity, renal, or mesenteric revasculariza- 
tion procedures) 2 The range of operative mortality 
rates used in the sensitivity analyses was selected to 
encompass both statewide and institutional experi- 
ences. 13 The probability of the transfusion-related 
complications and the ranges for the sensitivity anal- 
yses were obtained from review of the literature and 
discussion with local consultants. 
Medical costs. The costs of the CS, allogenic 
PRBCs, and the transfusion-related complications 
were obtained from the Office of Clinical Resource 
Management at the University of Florida Shands 
Hospital. The range of values used in the sensitivity 
analyses was determined from the institutional data, 
review of the literature, and discussion with local 
consultants. Direct variable costs were used for the 
analysis rather than total costs or charges because 
they most accurately reflect he cost of two alterna- 
Table I I .  CS salvage and perioperative 
PRBC transfusions 
Indication for Allogenic PRBC CS salvage 
reconstruction (units) (units) 
AAA 
All AAAs (N = 63) 2.8_+3.2 3.7_+3.2 
->6 cm (N = 34) 3.2 _+ 3.3 3.6 _+ 2.5 
Concomitant procedure 4.6 _+ 3.9 4.4 -+ 2.8 
(N = 14) 
Suprarenal crossclamp 4.4 _+ 3.4 5.2 _+ 3.6 
(N = 8) 
AIOD 
All AIODs (N = 75) 3.1 _+ 3.0 2.1 ± 1.7 
Concomitant procedure 4.8 _+ 3.6 2.3 _+ 1.4 
(N = 28) 
Suprarenal crossclamp 3.1 -+ 1.3 2.7 -+ 3.2 
(N = 10) 
tivc treatmcnt choices. The direct variable costs rep- 
resent he savings to the institution for each instance 
that the specific resource is not choscn. In contrast, 
the total cost of  a resource reflects cost that are 
incurred on each usc, as well as local fixed costs 
associated with the site of use, such as an operating 
room and its personnel. Hospital patient charges 
represent the highest level mix of local and distant 
institutional costs shifted among sites that typically 
generate revenues and losses. The cost of the CS was 
$477.74 and included the cost of the equipment, all 
disposable items, maintenance, and dedicated per- 
sonnel. The actual cost of transfusing a unit of allo- 
genie PRBCs is contingent on the quantity of units 
administered and the locale of the transfusion. The 
cost for antigen screening and the blood warming 
setup (operating room transfusion only) are assessed 
per multiple units, whereas the costs for the cross- 
match and the allogcnic ells themselves are assessed 
per unit. The cost of the allogenic PRBCs used in the 
analyses were calculated for operating room transfu- 
sions to simplify the convcrsion of CS units to allo- 
genie PRBC units and may overestimate he actual 
cost of the allogenic PRBCs. However, this should 
favor the cost-effectiveness of the CS. The cost of the 
first unit of  allogenic PRBCs transfused was $86.99 
and the cost for cach subsequent unit was $55.83. 
The cost of treating a nonfatal transfusion reaction 
($1800) for fiscal year i996 (FY96) was determincd 
by identifying all patients treated at our institution 
with that specific principal diagnostic ode. Similarly, 
all patients who were hospitalized with acute hepati- 
tis were identified by the principal diagnostic ode, 
and the average hospitalization cost ($33,000) was 
determined. The cost of evaluating a patient with 
mild acute hepatitis ($3000) and the ycarly fol- 
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Table II I . Red blood cell salvage and transfusion costs 
Reconstruction CS cost ($) PRBC cost ($) TXF Comp ($) Total cost ($) 
AAA--CS 477.74 187.48 5.51 670.73 
AAA--no CS 0 394.06 12.88 406.94 
AIOD--CS 477.74 204.23 5.56 687.53 
AIOD--no CS 0 321.48 9.37 330.85 
TXF Comp, Cost (in dollars) of all transfusion-related complications. 
Table IV. Determinants of life expectancy 
Life expectancy Perioperative death TXF Comp Postoperative life expectancy 
Reconstruction (yr ) * (QAL Ys) (QAL Ys) t (QAL Ys) 
AAA--CS 12.34568 0.77767 0.00176 11.56625 
AAA--no CS 12.34568 0.77752 0.00408 11.56408 
AIOD--CS 8.62069 0.49133 0.00096 8.12840 
AIOD--no CS 8.62069 0.49129 0.00162 8.12778 
*Life expectancy ofage- and sex-matched control population corrected for the disease-specific mortality rate. 
1"Cost (QALYs) of all allogenic PRBC transfusion-related complications. 
Table V. Impact of sensitivity analyses on cost-effectiveness 
AAA 
Variable Range of values ($/QAL Ys) AIOD ($/QAL Ys) 
Fatal transfusion react ion  0 .0000002-0 .00002 89 ,302-125,209 386,007-608,652 
Incidence HIV 0.00000022-0.000022 92 ,331-124,614 420,200-600,893 
Incidence Hepatitis C 0.00003-0.003 10,112-728,730 58,296-3,050,551 
Hepatitis C resolve 0.25-0.75 82,904-219,121 405,244-1,004,378 
Fulminant Hepatitis 0.0005-0.05 98,409-129,680 431,310-578,275 
low-up cost for a patient with chronic hepatitis 
($3000/yr) were determined from the average out- 
patient costs in FY96 for all patients who had a 
diagnostic code for acute hepatitis (n = 920) or 
chronic hepatitis (n = 179), respectively. The yearly 
cost of treating a patient with human immunodefi- 
ciency virus/acquired immune deficiency syndrome 
(HIV/AIDS; $10,000/yr) was determined from the 
sum of the average yearly inpatient, outpatient, anti 
emergency room costs of all patients (rl = 289) 
treated at our institution with a diagnostic ode for 
HIV during FY96. The costs associated with treating 
a patient with HIV or AIDS were not separated 
because individual diagnostic odes were not avail- 
able. The cost of a liver biopsy in FY96 ($400) was 
determined using the procedural code. Institutional 
data were not available on the costs of interferon 
therapy or for treating HTLV-related myelopathy. 
Estimation of these costs were obtained from the 
literature, and the values were increased 5% per year 
from the date the manuscript was accepted in an 
attempt o correct for inflation. All costs that were 
accrued in the future were discounted 5% per year. 
Life expectancy and QALYS. Life expectancy 
was determined using the declining exponential p- 
proximation of life expectancy 14,15 and data from the 
United States Vital Statistics. 16 Patient demographic 
data were obtained from the retrospective r view of 
the 138 aortic reconstructions. The mean ages 
(+SD) of the patients who underwent reconstruc- 
tion for AAA and AIOD were 71.1 + 6.4 (75% male) 
and 64.2 + 9.0 (52% male), respectively. The mean 
life expectancies were 12.3 years (0.081 mortality 
rate/yr) for the patients who had AAA and 17.6 
years (0.057 mortality rate/yr) for the patients who 
had AIOD. No disease-specific excess mortality risk 
was used for AAA because the patients who survive 
the operation should approach the life expectancy of 
their age- and sex-matched controls. 17,18 Patients 
who underwent reconstruction for AIODs were esti- 
mated to have a disease-specific excess mortality rate 
of 0.059/yr. 19 The survival duration for patients 
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with HIV/AIDS was estimated to be 9 years and was 
modeled in the tree using a Markov process, with the 
HIV stage lasting 7 years and the AIDS stage lasting 
2 years, s Patients who had chronic hepatitis were 
estimated to have a disease-specific excess mortality 
rate of 0.0035/yr, and survival duration was similarly 
modeled with a Markov process. 7 The life expectan- 
cies were adjusted to account for the presence of 
both short-term and long-term medical conditions. 
Each of the short-term medical conditions was as- 
signed a value to represent he QALYs lost. The 
long-term medical conditions were assigned a cor- 
rection factor elative to the condition, with a state of 
perfect health assigned a value of 1 and death as- 
signed a value of 0. The adjustment factors used for 
these specific disease states were obtained from re- 
view of the literature. 
RESULTS 
The routine use of the CS during elective infrare- 
hal aortic reconstructions was not found to be cost- 
effective in our practice by the decision analysis 
model. Use of the CS during reconstructions for 
AAA cost an additional $263.75 but saved only 
0.00218 QALYs, for a rate of $120,794/QALY. Use 
of the CS during reconstructions performed for 
AIOD was even more costly at $356.68 and resulted 
in a savings of only 0.00062 QALYs, for a rate of 
$578,275/QALY. The cost payoff in the decision 
analysis model was defined by the cost of the CS, the 
cost of the allogenic PRBCs, and the cost of all of the 
transfusion-associated complications (Table III). 
The majority of the total cost was for the CS and the 
allogenic PRBCs. The dollar costs of all of the poten- 
tial transfusion-related complications amounted to 
$1.98 and $1.80 per unit of allogenic PRBCs for 
reconstructions performed for AAA and AIOD, re- 
spectively. Similarly, the QALY payoffs in the model 
were determined by subtracting the QALY modifiers 
(such as perioperative death and chronic disease 
states) from the age- and sex-adjusted control life 
expectancies (Table IV). Perioperative death had the 
greatest impact on the QALYs lost, whereas the im- 
pact of the complications associated with a unit of 
allogenic PRBCs was minimal at 0.00063 QALYs 
(0.2 days) for AAA and 0.00031 QALYs (0.11 days) 
for AIOD. 
The sensitivity analyses determined that the cost- 
effectiveness of the CS was affected by the assump- 
tions used in the decision tree. During these analyses, 
the cost-effectiveness of the CS was reanalyzed in the 
model using a range of values (Table I) for each 
individual variable. The sensitivity analyses of several 
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Fig. 2. Impact of quantity of blood (units) salvaged by 
CS on cost-effectiveness (dollars/QALYs) determined 
from decision model is shown for aortic reconstructions 
performed for both AAA and AIOD. Cost-effectiveness 
threshold ($50,000/QALYs) isdefined. 
variables affected the calculated cost-effectiveness 
greater than 10%, with the incidence of hepatitis C 
having the most dramatic impact (Table V). The 
sensitivity analyses determined that the routine use of 
the CS would be cost-effective in our practice during 
aortic reconstructions for AAA if the incidence of 
hepatitis C per unit of allogenic PRBCs was tenfold 
higher than the baseline assumption. The remaining 
variables examined in the sensitivity analyses affected 
the cost-effectiveness <10%, with the majority, in- 
cluding the operative mortality rate, having minimal 
effects. 
The impact of the quantity of blood salvaged and 
life expectancy on the cost-effectiveness of the CS 
were examined. The quantity of blood salvaged (al- 
logenic transfusions avoided) was modeled by the 
decision tree using the baseline assumptions and pro- 
gressively arger CS salvage volumes (Fig. 2). The use 
of the CS became theoretically more cost-effective as
the salvage volume increased and fell below the cost- 
effectiveness cutoff after salvage of 5 units in patients 
with AAA (5 units, $53,660/QALYs) and after sal- 
vage of 6 units in patients with AIOD (6 units, 
$51,054/QALYs). These observations were ex- 
tended to our practice by examining the subset of 
patients in whom greater perioperative blood losses 
would have been predicted (Table VI). Although the 
difference in the red blood cell salvage and transfu- 
sion costs associated with the decision to use the CS 
decreased as a result of the increased salvage volumes 
in these subsets, the routine use of the CS was still 
not found to be cost-effective. Similarly, the impact 
of the life expectancy was modeled over a range of 5 
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Fig. 3. Impact of life expectancy ( ears) on cost-effective- 
ness (dollars/QALYs) determined for decision model is 
shown for aortic reconstructions performed for both AAA 
and MOD. Cost-effectiveness threshold ($50,000/ 
QALYs) is defined. 
to 25 years (Fig. 3). Use of the CS was theoretically 
cost-effective during aortic reconstructions for AAA 
if the life expectancy was greater than 20 years (20 
years, $50,217 QALYs). Conversely, and perhaps 
more importantly, use of the device would be even 
less cost-effective for indMduals with limited life ex- 
pectancies (AAA/5 years, $566,638 QALYs; 
A IOD/5  years, $1,333,657 QALYs). 
The impact of the per-unit allogenic PRBC costs, 
the CS costs, and the quantity of blood salvaged on 
the overall cost-effectiveness were examined in the 
model to extend the analyses to other institutions 
where the associated costs may be different. A theo- 
retical aortic reconstruction was modeled with a 5% 
perioperative mortality rate, a 10-year life expect- 
ancy, and a range of CS salvage volumes (Table VII). 
Predictably, the theoretical cost-effectiveness of the 
CS increased with both the per unit allogenic PRBC 
costs and the quantity of blood salvaged and de- 
creased with the CS cost. 
DISCUSSION 
The routine use of the CS during elective inffare- 
nal aortic reconstruction procedures was not found 
to be cost-effective in our practice. This supports the 
conclusions of several other studies encompassing 
vascular, s 6 orthopedic, 2° and cardiovascular p oce- 
dures, zl The major finding in the current study is the 
cost-ineffectiveness of the device, even when all of 
the complications associated with allogenic transfu- 
sions were factored into the analysis. Admittedly, the 
increased costs that resulted from the decision to use 
the CS were moderate; however, the benefits derived 
were minimal. This finding is consistent with the 
Table VI. Cost-effectiveness among subsets 
of aortic reconstructions 
Indication for Transfusion 
reconstruction costs ($) * $/QAL Ys 
AAA 
~6 cm (N = 34) 263.79 120,794 
Concomitant procedure 223.35 86,003 
(N = 14) 
Suprarenal crossclamp 177.12 57,710 
(N = 8) 
AIOD 
Concomitant procedure 345.15 510,879 
(N = 28) 
Suprarenal crossclamp 322.10 406,179 
(N = 10) 
*Difference in all perioperative r d blood cell salvage and transfu- 
sion costs based on the decision to use the CS. 
cost-ineffectiveness of preoperative autologous trans- 
fusion. 7,a,22 Indeed, the cost of  the transfusion-asso- 
ciated complications in both dollars and QALYs re- 
ported in these studies were comparable with our 
findings. 
The conclusions of the study are contingent on 
the design of the decision analysis model and the 
accuracy of  the values assigned to the individual vari- 
ables. These contingencies are not limited to our 
study but are intrinsic to the decision analysis tech- 
nique. The current model was designed to incorpo- 
rate all of the possible outcomes and costs associated 
with perioperative r d blood cell salvage and transfu- 
sions, and it was based on two published algo- 
rithms. 7,s It is conceivable that additional transfu- 
sion-related complications could potentially impact 
our conclusions. Indeed, HIV was not described 
until the early part of the last decade and provided 
one of the major impetuses for IOAT. Hepatitis G 
has recently been described, and its transmission may 
be similar to hepatitis C, although the natural history 
remains undefined. 23 In addition, no complications 
were ascribed to the cytomegalovirus, nor to the 
potential immunosuppression that may result from 
allogenic transfusions. The former was not incorpo- 
rated into the model because it is ubiquitous and is 
only a clinical concern to immunodeficient pa- 
tients, 24 whereas the latter was not included because 
the significance, causes, and incidence remain unre- 
solved? s Sensitivity analyses were used to test the 
stability or the robustness of the conclusions based 
on the assumptions used to define the variables. De- 
spite the potential for uncertainty, the conclusions 
were found to be consistent over a broad range of 
values for each variable with the one noted excep- 
tion. Among the variables, the values assigned to the 
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Tab le  V I I .  Effect o f  CS ($), PRBC ($), and salvage volume on cost-effectiveness 
2 umtssaNage 
CS cost(S) $50/PRBC $100/PRBC $150/PRBC $200/PRBC $250/PRBC 
200 121531 * * * * 
400 374248 247902 121557 * * 
600 626965 500619 374273 247928 121569 
800 879682 753336 626990 500644 374286 
1000 1132398 1006053 879707 753361 627003 
4 unitssaNage 
CS cost ($) $50/PRBC $100/PRBC $150/PRBC $200/PRBC $250/PRBC 
200 * * * * * 
400 121536 * * * * 
600 247887 121555 * * * 
800 374237 247906 121574 * * 
1000 500588 374256 247925 121600 * 
6 unitssa~age 
CS cost ($) $50/PRBC $100/PRBC $150/PRBC $200/PRBC $250/PRBC 
200 * * * * * 
400 * * * * * 
600 121547 * * * * 
800 205783 79463 * * * 
1000 290018 163698 * * * 
8 unitssa~age 
CScost($) $50/PRBC $100/PRBC $150/PRBC $200/PRBC $250/PRBC 
200 * * * * * 
400 * * * * * 
600 * * * * * 
800 121559 * * * * 
1000 184736 58426 * * * 
All values expressed as $/QALY. 
*Cost-effective based on a threshold of $50,000/QALY. 
quality o f  life adjustments and the costs are poten-  
tially the most  inexact. The quality o f  life adjust- 
ments attempt o quantitate the presence o f  chronic 
disease states relative to normal  health, but  the as- 
s ignment o f  these values is subjective. An attempt 
was made to minimize this subjective l imitat ion by 
using only previously publ ished values. The prob-  
lems associated with the quality o f  life adjustments 
were compounded by the minimal difference that 
resulted from the decision to use the CS; a small 
absolute rror in the QALYs saved would  potential ly 
have a large impact on the calculated cost-effective. 
ness (dol lars/QALYs) .  The accurate assessment o f  
medical costs is also difficult. Determinat ion o f  the 
CS and allogenic PRBC costs were relatively straight- 
forward because they involve a finite number  o f  i tem- 
ized costs. However ,  the costs associated with treat- 
ing specific disease states were subject to variability. 
Fortunately,  the aggregate red b lood cell salvage and 
transfusions costs were primari ly determined by the 
CS cost, the cost o f  the allogenic PRBCs, and the 
quantity o f  b lood salvaged. 
The application of  our conclusions to other prac- 
tice settings is cont ingent on the local costs and 
transfusion practices. An attempt was made to extend 
the usefulness of  the analysis to other practice set- 
tings by model ing a theoretic aortic reconstruction. 
Review o f  Table V I I  il lustrates how the cost-effec- 
tiveness of  the CS varies with these factors, specifi- 
cally, the cost o f  the CS, the cost o f  the allogenic 
PRBCs, and the quantity o f  b lood salvaged. This is 
further emphasized by comparison with the report  o f  
Goodnough et al.,6 who concluded that the CS was 
most beneficial dur ing aortic reconstructions when 
the CS volume returned was 750 ml, in contrast o 
1250 ml volume (5 PRBC unit equivalents) in the 
current study. The cost o f  the CS in their study was 
lower ($363 vs $478),  and the cost o f  a unit  o f  
al logenic PRBCs was greater ($155 vs $87 [first 
unit] and $56 [subsequent units]). The differences in 
the cost between the two analyses likely reflect both 
regional differences and account ing practices. The 
institutional cost o f  the allogenic PRBCs at our insti- 
tut ion is at the median among the University Hospi -  
tal Consort ium. Furthermore,  the institutional direct 
variable costs o f  both the CS and the allogenic 
PRBCs were used in our analysis rather than total 
cost or charges. Interestingly, the transfusion re- 
quirements in the current study Were comparable 
with Goodnough et al. 6 and are within the range of  
previous reports that documented  the use o f  IOAT 
during aortic reconstruction. 1-6,26,27 
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The threshold value of cost-effectiveness was de- 
fined as $50,000/QALYs. Although this value was 
defined from the literature, 9 1° acceptable values for 
cost-effective medical practices range from $20,000 
to 100,000/QALYs and reflect he lack of a consen- 
sus over the dollar value assessed to a year of life. 
Reanalysis of the data using the highest acceptable 
threshold ($100,000/QALYs) would have impacted 
our conclusions. The routine use of the CS would 
still not have been cost-effective using the baseline 
calculations. However, the conclusion would not 
have been supported over the range of all values used 
for the sensitivity analyses. Lastly, the cost-ineffec- 
tiveness of the CS may be placed in perspective by 
comparison with the calculated ollars/QALYs for 
other medical and surgical practices: coronary ar- 
tery bypass grafting, $6,000 to $50,000/QALy28; 
kidney transplantation, $18,000/QALy29; hemo- 
dialysis, $48,000/QALY3°; captopril treatment 
for hypertension, $79,000/QALY31; cholestyra- 
mine treatment for hyperlipidemia, $171,000/  
QALY. 32 
The three assumptions regarding the salvaged 
blood that were incorporated into the decision anal- 
ysis model may not be correct. However, two of the 
three assumptions bias in favor of the CS being 
cost-effective, and therefore the CS may actually be 
even more cost-ineffective than concluded. First, a 
unit of blood salvaged by the CS is probably not 
comparable with a unit of allogenic PRBCs, as the 
mean hematocrit level of the CS return is approxi- 
mately 50% compared with 70% for a unit of allo- 
genic PRBCs. 11,33 Second, it is unlikely that every 
unit of blood salvaged by the CS represents a unit of 
allogenic blood that would need to be transfused. 
This can not be determined from our data because 
the CS was used routinely in the study population 
and all of the salvaged blood was reinfused. Third, it 
is tmclear from the literature whether the CS is asso- 
ciated with any complications either from the me- 
chanical operation of the device or from rein fusion of 
the salvaged blood. 
Our study suggests that IOAT using the CS 
should be reserved for select indications. It becomes 
cost-effective in our practice when greater than 5 or 6 
units of blood are salvaged and is therefore likely to 
be worthwhile for ruptured aneurysms and for all 
complex, elective aortic reconstruction procedures, 
including suprarenal aneurysms, thoracoabdominal 
aneurysms, and aortocaval fistulae. A select group of 
patients who undergo infrarenal aortic reconstruc- 
tions will have blood losses that are sufficient o 
justify the cost-effective use of the CS; however, 
defining this group will likely require a multifactorial 
analysis from a large cohort of aortic reconstructions. 
Admittedly, IOAT affords several potential advan- 
tages during aortic reconstructions despite its cost 
ineffectiveness. It reduces the need for allogenic 
transfusions and therefore conserves blood bank re- 
sources. Furthermore, it is acceptable to most pa- 
tients who object to allogenic transfusions on either 
religious or other principles. 34 We have recently 
adopted a strategy that allows us to reap the benefits 
of the CS while still being cost-effective. In the subset 
of patients in whom we anticipate that the blood loss 
may be significant, he CS i s used initially as a reser- 
voir for the aspirated blood. The aspirated blood is 
processed and reinfused only if significant bleeding is 
encountered. The cost of using the CS as a reservoir 
is approximately $30, in contrast to the usual $478. 
Alternatively, the routine use of the CS may become 
cost-effective if either the cost of the IOAT devices 
can be substantially reduced or the cost of allogenic 
transfusions increases dramatically. 
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D ISCUSSION 
Dr.  Jack L. Cronenwett  (Lebanon, N.H.).  I compli- 
ment you on the use of  a complicated but appropriate 
technique that is effective in comparing different methods 
and looking at the tradeoffs between costs and benefits. I 
believe that your model is appropriate and I agree with 
most of  your assumptions. 
My major question relates to the cost that you have 
estimated both for an allogenic unit of blood and for a CS 
unit of  blood. In a recent article the Washington University 
group estimated that the cost of  a unit of  allogenic blood 
was $155, which is 2 to 3 times higher than your estimate. 
Furthermore, they estimated that the cost of  a CS unit was 
$360, which is 25% lower than your estimate. Obviously, 
those estimates would have a big impact on your model. So 
I wonder how confident you are about those baseline cost 
estimates and how applicable this is to other institutions. 
Overall, the results of  this study shouldn't surprise us. 
We know that our blood supply is very safe, that the 
complication rate is low, and that these are older patients 
who don't  live long enough to have many of these compli- 
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cations. We also have to remember, however, that allo- 
genic blood is a scarce resource, and if we abandon all 
autotransfusion would we in fact run the risk of decreasing 
the safety of this blood pool as more demand was placed on 
it? You will remember that when HW was detected 10 
years ago there was actually a significant increase in infec- 
tion because we had such a great reliance on allogenic 
blood. There may be new infections imilar to H IV  that 
become introduced in the future. Have you looked at the 
potential impact of abandoning autotransfusion i  your 
hospital on the ability of your blood bank to supply safe 
blood for all of these situations? 
Finally, I would like to point out that the threshold 
that society accepts or defines for cost-effective health care 
really depends on what society is willing to pay. There are 
many accepted practices, such as the use of medical therapy 
for hyperlipidemia, where the cost-effectiveness ratios are 
greatly in excess of $100,000 per quality adjusted life year. 
So it may be that for psychologic well being, society is 
willing to pay the cost of autotransfusion because of the 
great fear of blood-transmitted infection. 
I will just close by mentioning something you pointed 
out in your manuscript that is very important. It is possible 
in many cases to use only the reservoir system of the CS 
initially during an operation, and later, if the blood loss is 
sufficient, to attach the reservoir to the machine. This 
reduces the costs of consumable supplies in patients who 
don't  really require autotransfusion. 
Dr. Huber .  I will try to address all of your comments 
in order. 
I am very confident in our cost data. The accuracy is 
one of the strengths of our institution's clinical resource 
office. The cost of the CS and the cost of the PRBCs 
were defined as the direct variable cost, which represent 
the cost to the institution if the resource was not used. 
We included a table to make the analysis applicable to 
other institutions, because the conclusions are depen- 
dent on the quantity of blood, the cost of the CS, and 
the cost of the packed cells. 
My mission in this analysis was not to do away with the 
CS. Quite franldy, I like the device. It has multiple advan- 
tages, including conservation of resources, and it is helpful 
with Jehovah's Witnesses or others who object to transfu- 
sions for religious reasons. We have not gone back and 
looked at the impact on our blood bank. However, it 
would be a reasonable thing to do. 
As you mentioned, H1V was not described until the 
early 1980s. There are additional infectious transfusion 
complications that are evolving. Hepatitis G likely has the 
same transfusion-associated ransmission as hepatitis C, 
but the natural history is unknown. 
Lastly, we used $50,000 per QALY as our cost-effec- 
tiveness cutoff. There is no consensus in the literature on 
what people believe to be the value of a year of life. We 
reanalyzed the decision tree with $100,000 per QALY, and 
the majority of our conclusions held up. 
